Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral: Vanier Canada Graduate Scholarships

McGill University

$150,000.00

Prescribing Trends of Central Nervous System Depressants and the Risk of Adverse Respiratory Events in Patients with Chronic Obstructive Pulmonary Disease.

FY 2023-24

Summary
Supervisors: Prof. Samy Suissa and Prof Christel Renoux, McGill University Chronic Obstructive Pulmonary Disease (COPD) is a chronic lung disease that causes airway obstruction and breathing difficulties. It is the third leading cause of death globally, accounting for about 3.2 million deaths yearly. COPD often coexists with other diseases which could significantly worsen the course of the disease and overall quality of life. It is also worsened by the presence of chronic pain, which is highly common in patients with COPD, affecting 32% to 60% of individuals. Patients with COPD may be prescribed several medications to relieve pain and other symptoms and manage coexisting health conditions. Some of these medications such as some pain relievers and tranquilizers may increase the risk of breathing difficulties and death, particularly when taken together. Although several health agencies have warned about the risk of adverse respiratory events associated with these pain relievers and tranquilizers, available evidence suggests that some of these medications may be commonly prescribed to patients with COPD. However, prescription patterns over time for these drugs, alone or in combination, remain unknown. Moreover, while medications such as opioids have been shown to increase the risk of adverse respiratory events, there is limited information on the potential risk associated with the concurrent use of these medications in this vulnerable population. It is important to assess the use and safety of these medications in patients with COPD due to their declining lung function and increased risk of respiratory depression and death. Thus, I aim to describe trends in the use of pain relievers and tranquilizers (initiation, annual prescription, co-prescription) in patients with COPD over the last 20 years and estimate the risk of adverse respiratory events associated with the concurrent use of these medications using a large nationally representative cohort of patients with COPD.
Program
Doctoral: Vanier Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
495842
Name
Olaoye Omotayo C
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Clinical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Prescribing Trends of Central Nervous System Depressants and the Risk of Adverse Respiratory Events in Patients with Chronic Obstructive Pulmonary Disease.
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Central Nervous System Depressants; Chronic Obstructive Pulmonary Disease; Drug Safety; Drug Utilization; Polypharmacy; Prescription Trends; Respiratory Health
Abstract
Supervisors: Prof. Samy Suissa and Prof Christel Renoux, McGill University Chronic Obstructive Pulmonary Disease (COPD) is a chronic lung disease that causes airway obstruction and breathing difficulties. It is the third leading cause of death globally, accounting for about 3.2 million deaths yearly. COPD often coexists with other diseases which could significantly worsen the course of the disease and overall quality of life. It is also worsened by the presence of chronic pain, which is highly common in patients with COPD, affecting 32% to 60% of individuals. Patients with COPD may be prescribed several medications to relieve pain and other symptoms and manage coexisting health conditions. Some of these medications such as some pain relievers and tranquilizers may increase the risk of breathing difficulties and death, particularly when taken together. Although several health agencies have warned about the risk of adverse respiratory events associated with these pain relievers and tranquilizers, available evidence suggests that some of these medications may be commonly prescribed to patients with COPD. However, prescription patterns over time for these drugs, alone or in combination, remain unknown. Moreover, while medications such as opioids have been shown to increase the risk of adverse respiratory events, there is limited information on the potential risk associated with the concurrent use of these medications in this vulnerable population. It is important to assess the use and safety of these medications in patients with COPD due to their declining lung function and increased risk of respiratory depression and death. Thus, I aim to describe trends in the use of pain relievers and tranquilizers (initiation, annual prescription, co-prescription) in patients with COPD over the last 20 years and estimate the risk of adverse respiratory events associated with the concurrent use of these medications using a large nationally representative cohort of patients with COPD.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Olaoye, Omotayo C
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
McGill University - $150,000 Grant (2023-24) | Canada Spends